Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for ...

Novel small molecule inhibitors show promising efficacy in endometrial cancer, with ongoing trials expanding treatment ...

A study led by researchers at Moffitt Cancer Center found that normal cells surrounding a tumor, known as cancer-associated ...

A team of Australian researchers have developed a new targeted therapeutic approach that could improve treatment for ...

A dual-target CAR T cell therapy approach shows promise for slowing tumor growth in a notoriously aggressive and fast-growing brain cancer. Tumors became smaller after the experimental CAR T cell ...

Targeting two brain tumor-associated proteins -- rather than one -- with CAR T cell therapy shows promise as a strategy for reducing solid tumor growth in patients with recurrent glioblastoma (GBM), ...

The therapy is a highly advanced form of radiation therapy that uses charged particles in the form of a proton that that gets ...

Researchers, led by the University of Melbourne's Professor Laura Mackay, a Laboratory Head and Immunology Theme Leader at the Peter Doherty Institute of Infection and Immunity (Doherty Institute), in ...

BOSTON & SHENZHEN, China--(BUSINESS WIRE)--Signet Therapeutics, a clinical-stage biotech company leveraging organoid- and AI-driven cancer drug discovery, announced that the U.S. Food and Drug ...